



**MARYLAND**  
Department of Health

**MARYLAND ADVISORY BOARD ON  
PRESCRIPTION DRUG MONITORING (PDMP)**

**July 17, 2018  
2:00PM to 3:30 PM**

**TELECONFERENCE CALL**



**Attendees**

**Advisory Board**

Audrey Clark, MPA, Chair  
Daniel M. Ashby, MS, FASHP  
Amit Bhargava, MD, MS, RMSK  
Richard DeBenedetto, PharmD, MS,  
AAHIVP  
Lenna Israbian-Jamgochian, PharmD, RPh  
Bonnie Oettinger, RN, MGA  
Mark D. Olszyk, MD, MBA, CPE, FACEP,  
FACHE, FFSMB

Orlee Panitch, MD  
Derek Peck  
Larry Polsky, MD, MPH, FACOG  
Joseph Scalese III, MD  
Amar Setty, MD  
David Sharp, PhD  
Gail Shorter, DNP  
Michael Vaughn

**Advisory Board Not Present**

Thomas Bond  
Zachery Chatter, DPM  
David Gottlieb, DPM  
Arthur Jee, DMD  
Chris Jillson, MD  
Marcus Jones  
Stephen A. Nichols, MD, FAAP, FAAMR

**Board Adjunct:** Linda Bethman, JD, MA, Office of the Attorney General, MDH

**CRISP Representation**

Lindsey Ferris, MPH  
Rhonda Moody  
Camaryn Richmond

**MDH Staff**

Tryphena Barnes  
Anna Gribble, MSW, MPH  
Kate Jackson, MPH  
Katherine Johnson  
Casey Lyons, MPH

Vijay Murthy, MPH  
Sara Roberson, MSW  
Kathleen Rebbert-Franklin, LCSW  
Mary Viggiani, LCSW-C, LCADC

## **Public**

Rianna Matthews-Brown, JD  
Leslie Grant, DDS

## **Minutes**

### **I. Roll Call, Agenda Review, and Approval of Minutes:**

PDMP Advisory Board call-based meeting opened with roll call of attendees. Agenda was reviewed and it was requested that any corrections to minutes be provided to Kate Jackson via email ([kate.jackson@maryland.gov](mailto:kate.jackson@maryland.gov)).

### **II. PDMP Use Mandate Implementation:**

Sara Roberson, Assistant Director of the Behavioral Health Administration (BHA) Office of PDMP and Overdose Prevention Applied Data Programs (PDMP/OPADP) gave a brief presentation update on the PDMP Use Mandate that went live on July 1, 2018 (PPT slides available). A mass email using GovDelivery was sent out on 5/30/ 2018 to PDMP-registered prescribers and pharmacists using the email address on file with CRISP. The GovDelivery emailing service provided open rates, which allowed us to know if an email was opened or not. To all who did not open first email, a second email was sent out on June 12, 2018.

A letter from the Secretary and a Use Mandate Fact Sheet were sent to both prescribers and pharmacists. The prescribers were also sent CDC prescribing guidelines and a Billing for Suicide Risk Assessment. On June 20, 2018, the prescriber mailing was sent out based on Office of Controlled Substances Administration mailing addresses to all CDS prescribers (33,988) total. The pharmacist mailing went out to all licensed pharmacists (11,700) based on addresses from Board of Pharmacy on June 15, 2018. Based on the large volume of letters that went out, we are happy to report that the return rate has been very low.

BHA has been collaborating with CRISP, the Maryland Addiction Consultation Service (MACS) and Med Chi to assist providers in preparing for the Use Mandate. CRISP Operation Support Staff handles the technical questions, and the PDMP Use Mandate Call Center at Med Chi handles inquiries around implementation. MACS handles clinical questions.

The majority of calls have come from people needing CRISP/PDMP password assistance. There have also been questions about exemptions from the mandate and about specific drugs or scenarios. Based on questions and feedback from providers we are continuing to build FAQs.

From the end of May to July 1, CRISP received 519 calls and Med Chi received 418 calls. In the first week of July, CRISP received 135 calls and Med Chi received 76 calls. MACS received 7 calls before July 1 and one call in the first week of July.

Other outreach measures include emails to boards, professional organizations, health officers, Beacon Health and Medicaid. Ads were placed in the Maryland Academy of Family Physicians

Maryland Family Doctor Magazine and the Maryland Nurse's Association newsletter. Also, Kate has attended meetings with health officers and board directors.

Next steps for the Use Mandate:

- PDMP Video vignettes-Autumn 2018 (Anna Gribble has been instrumental in working on these.)
- Additional Fact Sheets: Delegates, Dos/Don'ts, Integration
- Updates to FAQs-ongoing
- Update PDMP website with clinical resources (Anna Gribble is also working on these updates.)

### III. Provider Education:

Anna Gribble, Health Policy Analyst in the BHA Office of Prevention gave a presentation on a survey of other state PDMP educational offerings for prescribers and pharmacists. She described the educational resources falling under four main categories: Pain management, substance misuse, engaging patients, and prescribing resources.

Anna identified the three main areas common to all of the educational efforts:

- I see something suspicious in the PDMP, what do I do?
- I have an alert that my patient has overdose, what do I do?
- I suspect another provider is negligent or harmful, what do I do?

Questions for the PDMP Advisory Board to consider:

- Where should we prioritize our efforts?
- Recommended methods for disseminating resources?
- Feedback on messaging?
- Where are the gaps, are there other resources that would be helpful?

The Board gave feedback on the presentation:

- **Other states' PDMPs:** Kate solicited input regarding clinicians' use of other states' PDMP's and educational materials. What do they like better compared with Maryland's? Are there any resources that have been helpful?
- **Outreach:** In looking for practical ways to implement PDMP education, Dr. Scalese suggested presenting at established meetings, particularly for primary care physicians under the topic of "Best Practices." Is there a way to imbed PDMP in a practice's EHR to help to prompt questions? How can referrals and resources be automated into the current practice workflow?
- **Red Flags:** Dr. Debenedetto mentioned that prioritizing collaboration among providers when red flags are identified is important: "How do I do this?" education, What national organizations have models? What work is being done by our local institutions, such as Hopkins? How do we facilitate delivering clinical information: CME's, departmental meetings? What has impact on a daily basis?.

- **Payment Method in PDMP:** Dr. Scalese questioned how payment method was listed on dispenses in the PDMP. There are payment methods, such as discount cards, that are inconsistently documented. Is there any guidance for dispensers as a whole? What do other states do? The PDMP reflects how payment method is recorded by the pharmacy.

Kate asked the Board to review the materials and talk with colleagues and provide feedback regarding the professional organizations or groups that we should be working with to forward the momentum on this.

#### **IV. Public Comment Session:**

Dr. Gant asked if the FAQ sheets that include the Use Mandate have been developed yet for those who of us who are out in the prescribing community, for our different specialty areas to distribute? She also commented on the registration process, stating that she was very pleased with how seamless the process was. Kate directed her to the PDMP website ([MarylandPDMP.org](http://MarylandPDMP.org)) for the legislation FAQ sheet, and the Use Mandate fact sheets for prescribers and for pharmacists.

Dr. Scalese asked Kate if she received the email from her my corporate office regarding partnership with the live PDMP information, and Kate did and forwarded it to CRISP; Mike is helping work on this. We're very excited to promote integration with the pharmacy systems.

Kate mentioned that a copy of today's slides was emailed out to Board members. For all public members on the call who would like a copy please send her an email. If you have any additional feedback or suggestions regarding the provider education piece, or if you hear anything that we need to know about around accommodation of the Use Mandate, please contact Kate at [kate.jackson@maryland.gov](mailto:kate.jackson@maryland.gov).

**Meeting Adjourned**